Cardiovascular disease in COPD: time to quash a silent killer

Lancet Respir Med. 2016 Sep;4(9):687-689. doi: 10.1016/S2213-2600(16)30243-0.

Authors

Charlotte E Bolton¹, Jennifer K Quint², Mark T Dransfield³

Affiliations

¹ Nottingham Respiratory Research Unit, School of Medicine, University of Nottingham, Nottingham, UK.
² Department of Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College London, UK.
³ Division of Pulmonary, Allergy & Critical Care Medicine, University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL 35294, USA. Electronic address: mdransfield@uabmc.edu.

PMID: 27599243
DOI: 10.1016/S2213-2600(16)30243-0

No abstract available

MeSH terms

Cardiovascular Diseases / complications*
Cardiovascular Diseases / mortality
Cardiovascular Diseases / therapy
Humans
Pulmonary Disease, Chronic Obstructive / complications*
Pulmonary Disease, Chronic Obstructive / mortality
Risk Factors